Decrease in cell proliferation by an matrix metalloproteinase inhibitor, doxycycline, in a model of immune-complex nephritis

Nephrology

Volumn 15, Issue 5, 2010, Pages 560-567

  Saglam, Funda ^a   Celik, Ali ^a   Tayfur, Devrim ^a   Cavdar, Zahide ^b   Yilmaz, Osman ^c   Sarioglu, Sulen ^a   Kolatan, Efsun ^c   Oktay, Gulgun ^d   Camsari, Taner ^a  

^a Department of Nephrology ^*  (Turkey)

^b Institute of Health Sciences   (Turkey)

^c Laboratory of Experimental Animals   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

doxycycline; extracellular matrix; glomerulonephritis; immune complexes; matrix metalloproteinase

Indexed keywords

BOVINE SERUM ALBUMIN; COLLAGEN TYPE 4; COMPLEMENT COMPONENT C3; DOXYCYCLINE; GELATINASE B; IMMUNOGLOBULIN G; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; FREUND ADJUVANT; GELATINASE A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MMP2 PROTEIN, RAT; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNE COMPLEX NEPHRITIS; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; JUXTAGLOMERULAR CELL; KIDNEY PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THERAPY EFFECT; ZYMOGRAPHY; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS; GLOMERULUS; IMMUNE COMPLEX DISEASES; METABOLISM; PATHOLOGY; TIME; WISTAR RAT;

ANIMALS; CELL PROLIFERATION; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DOXYCYCLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; FREUND'S ADJUVANT; GLOMERULONEPHRITIS; IMMUNE COMPLEX DISEASES; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; RATS; RATS, WISTAR; SERUM ALBUMIN, BOVINE; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77955061425     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01289.x     Document Type: Article

References (27)

1. Weber M. Basement membrane proteins. Kidney Int. 1992 41 : 620 628.
2. Harendza S, Schneider A, Helmchen U et al. Extracellular matrix deposition and cell proliferation in a model of chronic glomerulonephritis in the rat. Nephrol. Dial. Transplant. 1999 14 (12 2873 2879.
3. Liu S, Li Y, Zhao H et al. Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats. Mol. Cell. Biochem. 2006 284 (1-2 9 17.
4. Bauvois B, Mothu N, Nguyen J et al. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Nephrol. Dial. Transplant. 2007 22 (4 1115 1122.
5. Lovett DH, Johnson RJ, Marti HP et al. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am. J. Pathol. 1992 141 : 85 98.
6. McMillan JI, Riordan JW, Couser WG et al. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J. Clin. Invest. 1996 (15
7. McMillan JI, Riordan JW, Couser WG et al. J. Clin. Invest. 97 (4 1094 1101.
8. Akiyama K, Shikata K, Sugimoto H et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res. Commun. Mol. Pathol. Pharmacol. 1997 95 : 115 128.
9. Koide H, Nakamura T, Ebihara I et al. Increased mRNA expression of metalloproteinase- 9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. Am. J. Kidney Dis. 1996 28 (1 32 9.
10. Steinmann-Niggli K, Ziswiler R, Küng M et al. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J. Am. Soc. Nephrol. 1998 9 : 397 407.
11. Agan S, Sonmez S, Serdar M. The effect of topical doxycycline usage on gingival crevicular fluid MMP-8 levels of chronic and aggressive periodontitis patients: A pilot study. Int. J. Dent. Hyg. 2006 4 : 114 121.
12. Nicoud IB, Jones CM, Pierce JM et al. Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction. Cancer Res. 2007 (15 67 (6 2720 2728.
13. Kaufman TJ, Marx WF, Kallmes DF. A failure of matrix metalloproteinase inhibition in the prevention of rat intracranial aneurysm formation. Neuroradiology 2006 48 : 190 195.
14. Kadoglou NP, Liapis CD. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr. Med. Res. Opin. 2004 20 : 419 432.
15. Ahuja TS. Doxycycline decreases proteinuria in glomerulonephritis. Am. J. Kidney Dis. 2003 42 : 376 380.
16. Mirshafiey A, Borzooy Z, Abhari RS et al. Treatment of experimental immune complex glomerulonephritis by sodium alginate. Vascul. Pharmacol. 2005 43 (1 30 35.
17. Guray M, Sarioglu S, Turkmen M et al. Cyclosporine A toxicity in association with reduced renal mass. Transpant. Proc. 2003 35 : 3128 3133.
18. Newbold KM, Howie AJ, Koram A et al. Assessment of glomerular size in renal biopsies including minimal change nephropathy and single kidneys. J Pathol 1990 160 : 255 258.
19. Kleiner D, Stetler-Stevenson WG. Quantitative zymography: Detection of picogram quantities of gelatinases. Anal. Biochem. 1994 (1 218 325 329.
20. Kleiner D, Stetler-Stevenson WG. Anal. Biochem. 218 325 329.
21. Yamamoto T, Noble NA, Miller DE et al. Sustained expression of TGF-b1 underlies development of progressive kidney fibrosis. Kidney Int. 1994 45 : 916 927.
22. Floege J, Johnson RJ, Gordon K et al. Increased synthesis of extracellular matrix mesengial proliferative nephritis. Kidney Int. 1991 40 : 477 488.
23. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol. 2000 11 : 574 581.
24. Watson SA, Tierney G. Matrix metalloproteinase inhibitors: A review. BioDrugs 1998 9 : 325 335.
25. Zhang ZG, Liu XG, Chen GP et al. Significance of MMP-2 and TIMP-2 mRNA expressions on glomerular cells in the development of glomerulosclerosis. Med. Sci. J. 2004 19 : 84 8.
26. Gomez DE, Alonso DF, Yoshiji H et al. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur. J. Cell Biol. 1997 74 : 111 122.
27. Sanders JS, Van Goor H, Hanemaaijer R et al. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 2004 19 (6 1412 1419.